NeoPath expands share of US market for Pap smears
This article was originally published in Clinica
NeoPath, the manufacturer of the AutoPap primary screening system for cervical cancer, has formed supply agreements with SmithKline Beecham and Kaiser Permanente. The company says that, with the two deals, it will have nearly 15% of the market for bulk testing of Pap smears in the US.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.